We used data from a nationwide large scale registry dedicated to myocardial infarction.
Design A prospective cohort study using data from a nationwide large scale registry.
Other studies using large scale registry data in Japan were able to partially address the time dependent imbalance.
Further investigation in the form of a randomized controlled trial, its variations, or continuous large scale registry analyses is warranted for evaluation of this technology.
Research based on large-scale registries (with the records of millions of patients) used, e.g. to determine disease prevalence would need the informed consent of all individual patients.
Despite obvious limitations, data from large-scale registries provide useful insights on the feasibility and safety of new therapeutic strategies, as well as on off-label indications.
They should form an integral part of any outcome monitoring efforts but are often omitted from large-scale registries because of constraints on the amount of data these registries can collect.
The Collaborative Transplant Study CTSS) based in Europe [ 25], the Scientific Registry of Transplant Recipients (SRTR) in USA [ 26], and the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry are large-scale registries [ 27].
Other large-scale registries have also shown a difference in the incidence of CAD-related clinical events among patients in different countries, highlighting higher mortality rates in North American populations and lower mortality rates in Japanese and Chinese populations (12, 13).
The creation of a large-scale registry will make it possible to identify specific CM (i.e., refractory CM) subgroups, based on clinical and biological features.
However, the proven validity of more robust and cumbersome patient-reported outcome instruments (PROi) must be balanced with what is feasible to apply in large-scale registry efforts.
